
Pharvaris B.V. (PHVS) Stock Forecast & Price Target
Pharvaris B.V. (PHVS) Analyst Ratings
Bulls say
Pharvaris is a late-stage biopharmaceutical company that specializes in developing novel, oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE) attacks. Their main pipeline candidate, deucrictibant, has shown positive data in both Phase 2 prophylaxis and on-demand studies in HAE. While there are potential risks in focusing on one mechanism of action and therapeutic indication, Pharvaris has discussed exploring other B2-receptor-mediated diseases, providing some therapeutic diversification. With their current financials and ongoing clinical trials, Pharvaris has the potential to gain market share in the maturing HAE therapeutic landscape, but may need to differentiate deucrictibant from other available options. The success of their ongoing Phase 3 study and subsequent regulatory approvals will be key factors in their future commercial success.
Bears say
Pharvaris is a late-stage biopharmaceutical company with a negative outlook due to concerns about the success of their upcoming CHAPTER-3 data readout for their drug deucrictibant in the prophylactic setting. While there are similarities between their Phase 2 study and CHAPTER-3, there is still uncertainty about the drug's ability to effectively reduce attack rates. If efficacy falls short and the prophy opportunity is removed, the company's fair value could decrease to $29/share. Furthermore, the company's planned launch of deucrictibant in mid-2027 and introduction of FY33 estimates indicate a longer timeline for potential profitability, which could impact investor confidence.
This aggregate rating is based on analysts' research of Pharvaris B.V. and is not a guaranteed prediction by Public.com or investment advice.
Pharvaris B.V. (PHVS) Analyst Forecast & Price Prediction
Start investing in Pharvaris B.V. (PHVS)
Order type
Buy in
Order amount
Est. shares
0 shares